Objectif
RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Thème(s)
Appel à propositions
FP7-HEALTH-2010-single-stage
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
13284 Marseille
France
Voir sur la carte
Participants (23)
23562 Lubeck
Voir sur la carte
3000 Leuven
Voir sur la carte
2333 ZA Leiden
Voir sur la carte
3015 GD Rotterdam
Voir sur la carte
75724 Paris
Voir sur la carte
69120 Heidelberg
Voir sur la carte
Participation terminée
6525 XZ Nijmegen
Voir sur la carte
Participation terminée
01445 RADEBEUL
Voir sur la carte
OX1 2JD Oxford
Voir sur la carte
75794 Paris
Voir sur la carte
28006 Madrid
Voir sur la carte
CB2 8AL CAMBRIDGE
Voir sur la carte
Participation terminée
CH-8005 ZUERICH
Voir sur la carte
6020 Innsbruck
Voir sur la carte
20148 HAMBURG
Voir sur la carte
201203 SHANGHAI
Voir sur la carte
305606 DAEJEON
Voir sur la carte
320 Jhongli
Voir sur la carte
20122 Milano
Voir sur la carte
Participation terminée
04109 Leipzig
Voir sur la carte
3001 Heverlee
Voir sur la carte
3584 CS Utrecht
Voir sur la carte
14195 Berlin
Voir sur la carte